Literature DB >> 18194353

Analysis of the CC chemokine receptor 5Delta32 polymorphism in pediatric liver transplant recipients.

Louise Fischer-Maas1, Reinhard Schneppenheim, Florian Oyen, Enke Grabhorn, Andrea Richter, Lutz Fischer, Rainer Ganschow.   

Abstract

In adult liver graft recipients, it has been shown that certain chemokine polymorphisms (CCR5Delta32) may correspond to ischemic type biliary lesions leading to chronic graft dysfunction. The aim of our present study was to assess the importance of CCR5Delta32 polymorphism in a cohort of pediatric liver graft recipients with regard to acute or chronic graft dysfunction. A total of 137 children post-liver transplantation have been included for genetic analysis (CCR5Delta32 polymorphism), and the incidence of acute and chronic graft dysfunction was analyzed. The most common diagnosis leading to LTx was biliary atresia (56.2%), the median age was 14 months, and 33.5% of the patients received a living-related graft. In all, 110 of the subjects were found to have the CCR5 wild type, 25 children were heterozygous for CCR5Delta32, and two patients were homozygous. Of 137, 44 (32.1%) developed acute graft rejection, nine out of 137 (6.6%) chronic graft dysfunction (vanishing bile duct syndrome), and 84 (61.3%) children had neither acute nor chronic graft rejection. There was no significant correlation between acute graft rejection or chronic graft dysfunction and the CCR5Delta32 allele in the study population. We conclude that CCR5Delta32 polymorphism may not play a role in acute or chronic liver graft dysfunction in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18194353     DOI: 10.1111/j.1399-3046.2007.00900.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

Review 1.  Chemokine-directed strategies to attenuate allograft rejection.

Authors:  Austin D Schenk; Joshua M Rosenblum; Robert L Fairchild
Journal:  Clin Lab Med       Date:  2008-09       Impact factor: 1.935

Review 2.  Chemokines in chronic liver allograft dysfunction pathogenesis and potential therapeutic targets.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan
Journal:  Clin Dev Immunol       Date:  2013-12-08

3.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.